Skip to main content
iNtRON Biotechnology, Inc. logo

iNtRON Biotechnology, Inc. — Investor Relations & Filings

Ticker · 048530 ISIN · KR7048530000 KO Manufacturing
Open in API
Filings indexed 268 across all filing types
Latest filing 2025-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 048530

About iNtRON Biotechnology, Inc.

https://intronbio.com:6001

iNtRON Biotechnology, Inc. is a biotechnology company specializing in solutions for infectious diseases. Its core activities are centered on three main pillars: bio-new drugs, molecular diagnostics, and molecular biology reagents. The company's therapeutic pipeline focuses on developing novel treatments for drug-resistant super-bacteria, creating antibiotic alternatives and other bio-active agents to address the challenge of antimicrobial resistance (AMR). In its diagnostics division, iNtRON develops and manufactures detection kits and assays, primarily based on real-time PCR technology, for the rapid identification of infectious organisms. The company also provides a range of molecular reagents for research and has commercialized antibiotic alternative products for the animal health market.

Recent filings

Filing Released Lang Actions
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'iNtRON Biotechnology, Inc.' covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial information, business descriptions, and management disclosures required by the Financial Supervisory Service and the Korea Exchange. This fits the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership, specifically regarding collateral agreements (주식 담보 계약 일부 변경). This type of filing is a mandatory disclosure for major shareholders and does not fit into categories like Annual Reports, Earnings Releases, or Proxy Statements. Therefore, it is classified as a Regulatory Filing.
2025-05-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and collateral agreements (stock pledge contracts) of major shareholders and special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-04-18 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities regarding the termination of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This type of filing relates to the company's capital structure and treasury stock management. Since the document details the termination of a share repurchase trust, it falls under the category of 'Transaction in Own Shares' (POS), which covers share buybacks and related contractual changes.
2025-04-09 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities regarding the termination of a trust agreement for the acquisition of treasury shares (자기주식취득 신탁계약 해지 결정). This falls under the category of company share buyback or treasury share management activities. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct classification for reports concerning the company buying back or selling its own shares.
2025-04-09 Korean
신탁계약해지결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '신탁계약해지결과보고서' (Report on the Termination of a Trust Agreement) filed by Intron Biotechnology with the Financial Supervisory Service (FSS) of South Korea. It details the termination of a share repurchase trust contract, including the final amounts, transaction history, and the resulting status of treasury shares. This type of filing is a regulatory disclosure regarding the company's capital management and share repurchase activities, which falls under the category of Transaction in Own Shares (POS).
2025-04-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.